Back to Search
Start Over
Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.
- Source :
-
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Apr 15; Vol. 27 (8), pp. 2301-2313. Date of Electronic Publication: 2021 Jan 08. - Publication Year :
- 2021
-
Abstract
- Purpose: On the basis of the recent discovery of mutations in Bruton tyrosine kinase ( BTK ) in follicular lymphoma, we studied their functional properties.<br />Experimental Design: We identified novel somatic BTK mutations in 7% of a combined total of 139 follicular lymphoma and 11 transformed follicular lymphoma cases, none of which had received prior treatment with B-cell receptor (BCR) targeted drugs. We reconstituted wild-type (WT) and mutant BTK into various engineered lymphoma cell lines. We measured BCR-induced signal transduction events in engineered cell lines and primary human follicular lymphoma B cells.<br />Results: We uncovered that all BTK mutants destabilized the BTK protein and some created BTK kinase-dead mutants. The phospholipase C gamma 2 (PLCγ2) is a substrate of BTK but the BTK mutants did not alter PLCγ2 phosphorylation. Instead, we discovered that BTK mutants induced an exaggerated AKT phosphorylation phenotype in anti-Ig-treated recombinant lymphoma cell lines. The short hairpin RNA-mediated knockdown of BTK expression in primary human nonmalignant lymph node-derived B cells resulted in strong anti-Ig-induced AKT activation, as did the degradation of BTK protein in cell lines using ibrutinib-based proteolysis targeting chimera. Finally, through analyses of primary human follicular lymphoma B cells carrying WT or mutant BTK , we detected elevated AKT phosphorylation following surface Ig crosslinking in all follicular lymphoma B cells, including all BTK -mutant follicular lymphoma. The augmented AKT phosphorylation following BCR crosslinking could be abrogated by pretreatment with a PI3Kδ inhibitor.<br />Conclusions: Altogether, our data uncover novel unexpected properties of follicular lymphoma-associated BTK mutations with direct implications for targeted therapy development in follicular lymphoma. See related commentary by Afaghani and Taylor, p. 2123 .<br /> (©2021 American Association for Cancer Research.)
- Subjects :
- Agammaglobulinaemia Tyrosine Kinase metabolism
Cell Line, Tumor
Class I Phosphatidylinositol 3-Kinases antagonists & inhibitors
Class I Phosphatidylinositol 3-Kinases metabolism
DNA Mutational Analysis
Gene Knockdown Techniques
HEK293 Cells
Humans
Loss of Function Mutation
Lymphoma, Follicular pathology
Mutagenesis, Site-Directed
Phospholipase C gamma metabolism
Phosphorylation drug effects
Phosphorylation genetics
Primary Cell Culture
Protein Stability
Agammaglobulinaemia Tyrosine Kinase genetics
Lymphoma, Follicular genetics
Proto-Oncogene Proteins c-akt metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1557-3265
- Volume :
- 27
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publication Type :
- Academic Journal
- Accession number :
- 33419778
- Full Text :
- https://doi.org/10.1158/1078-0432.CCR-20-3741